Nektar Therapeutics (NKTR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

8
Nektar Therapeutics (NKTR) Q2 2026: $1B Cash Fuels Phase 3 Launch for Rezpegaldesleukin in Atopic Dermatitis
August 17, 2026
6
Nektar Therapeutics (NKTR) Q1 2026: Phase 3 Readiness Advances, 9-12 Month Durability Data in Focus
May 08, 2026
9
Nektar Therapeutics (NKTR) Q4 2025: Cash Surges to $476M, Accelerating Phase III Immunology Push
March 13, 2026
8
Nektar Therapeutics (NKTR) Q3 2025: Cash Runway Extended to Q2 2027 as RESPEG Differentiation Deepens
November 07, 2025
8
Nektar Therapeutics (NKTR) Q2 2025: $115M Raise Extends Runway, RESPEG Poised for Phase 3 in $15B Derm Market
August 08, 2025
10
Nektar Therapeutics (NKTR) Q1 2025: Pipeline Progress Drives Focus on Immunology with $220M Cash Runway
May 09, 2025
10
Nektar Therapeutics (NKTR) Q1 2025: Rezpegaldesleukin Phase 2b Data Set to Define Next Growth Chapter
May 08, 2025
10
Nektar Therapeutics (NKTR) Q4 2024: $40M Facility Sale Boosts Cash, Phase 2b Data Catalysts Set for 2025
March 12, 2025

Browse all companies